The FDA has delayed potential approval of a cancer treatment that utilizes Exelixis in combination with Roche's Tecentriq.

The entities involved

• Exelixis →

  American biotechnology company

  Nothing else this week.

• Hoffmann-La Roche →

  Swiss healthcare company

  • Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sun 02:44
  • Hoffmann-La Roche opened a new R&D center in Boston.Sat 11:08
• Food and Drug Administration →

  government organization in Nonthaburi, Thailand

  • Trump is expected to nominate Heidi Overton to lead the Food and Drug Administration.Mon 15:49
  • In 2007, CBS broadcast featured Andrews, Cordes, and Couric criticizing the Food and Drug Administration's problems.Mon 12:46

Related events

• BioNTech is listed on Nasdaq and is advancing pancreatic cancer trials using Roche's Tecentriq, while also partnering with Genentech.Sep 8
• The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.Sep 14